Mather L E, Runciman W B, Ilsley A H, Thomson K R, Goldin A R
Br J Clin Pharmacol. 1981 Sep;12(3):319-25. doi: 10.1111/j.1365-2125.1981.tb01220.x.
1 Chlormethiazole was used as a basal sedative for patients undergoing angiographic procedures. 2 Blood samples were drawn opportunistically to examine chlormethiazole extraction across liver, lungs and kidney. 3 Extraction across liver was typically 70-80% and apparently unrelated to input concentrations. Evidence for extraction across lung and kidney was inconclusive but these could each be approximately 20%. 4 Pharmacokinetics of chlormethiazole derived from compartment models were in accord with previous reports and were characterised by a high total body clearance (1-1.5 l/min). 5 Postural changes associated with the radiological procedures caused fluctuating blood concentrations which appear as noise in curve fitting procedures. 6 Pharmacokinetic properties derived from compartment theory cannot cope with these perturbations because of the restriction imposed by time averaging (i.e. mean clearances, half-lives and volumes are produced). Systematic studies of pharmacokinetic properties of perfusion-limited drugs such as chlormethiazole must be developed in such a way as to allow for independent variation of flow and extraction.
氯美噻唑用作接受血管造影检查患者的基础镇静剂。
随机采集血样以检测氯美噻唑在肝脏、肺和肾脏的摄取情况。
肝脏摄取率通常为70 - 80%,且明显与输入浓度无关。肺和肾脏摄取的证据不明确,但各自可能约为20%。
源自房室模型的氯美噻唑药代动力学与先前报道一致,其特征为全身清除率高(1 - 1.5升/分钟)。
与放射学检查相关的体位变化导致血药浓度波动,这在曲线拟合过程中表现为噪声。
由于时间平均的限制(即产生平均清除率、半衰期和容积),源自房室理论的药代动力学特性无法应对这些干扰。必须以允许血流和摄取独立变化的方式开展对灌注受限药物如氯美噻唑药代动力学特性的系统研究。